OBJECTIVE： To observe clinical efficacy and safety of capecitabine and tegafur gimeracil and oteracil potassium synchronous radiotherapy in the treatment of recurrence after radical resection of colon cancer. METHODS： A total of 150 patients with recurrent after radical resection of colon cancer in our hospital during Jan. 2012-Dec. 2012 were divided into group A and B according to random number table， with 75 cases in each group. Both groups received three-dimensional conformal radiotherapy. Group A was additionally given capecitabine 2.5 g. Group B was additionally given tegafur gimeracil and oteracil potassium， 40 mg，bid for body surface area ＜1.25 m2， 50 mg，bid for body surface area ranged 1.25-1.50 m2 and60mg，bid for body surface area ＜1.50 m2. Clinical efficacies of 2 groups were compared； 1-year， 2-year， 3-year survival and Ⅲ-Ⅳ degree toxic effect were followed up. RESULTS： The total response rate of group B was 86.67％， which was significantly higher than 66.67％ of group A， with statistical significance（P＜0.05）. 1-year， 2-year， 3-year survival rates of group B were 93.335， 72.00％， 58.67％， which was significantly higher than 74.67％， 53.33％， 41.33％， with statistical significance （P＜0.05）. The median disease progression time of group A was 8.0 months， which was significantly shorter than 9.5 months of group B， with statistical significance （P＜0.05）. There was no statistical significance in Ⅲ-Ⅳ degree toxic effect between 2 groups （P＜0.05）. CONCLUSIONS： Compared with capecitabine， tegafur gimeracil and oteracil potassium combined with three-dimensional conformal radiotherapy show significant therapeutic efficacy for recurrence after radical resection of colon cancer， can control disease progression， prolong the survival time and don’t increase the risk of toxic effects.